Vusolimogene oderparepvec is a genetically modified HSV-1 oncolytic viral immunotherapy used intratumorally with nivolumab for unresectable advanced cutaneous melanoma refractory to anti-PD-1 therapy, replicating selectively in tumor cells and expressing GALV-GP-R– and GM-CSF to drive anti-tumor immunity. The virus is engineered to express a fusogenic glycoprotein derived from gibbon ape leukemia virus (GALV-GP-R–) and human granulocyte-macrophage colony-stimulating factor (GM-CSF), and has its HSV-1 neurovirulence factor ICP34.5 and antigen-presentation inhibitor ICP47 genes deleted.
- Primary indication
- Vusolimogene oderparepvec-wtpg is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.Curator reviewed · 1 structured indication
- First approval
- United States, 2026
- Brand names
Resolves to
What you can answer from here — as of September 14, 2026
Which other approved drugs treat the same conditions as Vusolimogene oderparepvec, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account